NURIX THERAPEUTICS, INC. Debt Securities Available For Sale Excluding Accrued Interest Noncurrent
NURIX THERAPEUTICS, INC. (NRIX) had Debt Securities Available For Sale Excluding Accrued Interest Noncurrent of $0 as of 2024-11-30, per its 10-K filed 2025-01-28.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent · last filed 2025-01-28
- 2024-11-30: Debt Securities Available For Sale Excluding Accrued Interest Noncurrent $0.00.
- 2024-08-31: Debt Securities Available For Sale Excluding Accrued Interest Noncurrent $9.47M.
- 2024-05-31: Debt Securities Available For Sale Excluding Accrued Interest Noncurrent $9.38M.
- 2023-11-30: Debt Securities Available For Sale Excluding Accrued Interest Noncurrent $7.42M.
| Period end | Debt Securities Available For Sale Excluding Accrued Interest Noncurrent |
|---|---|
| 2024-11-30 | $0.00 10-K · filed 2025-01-28 |
| 2024-08-31 | $9.47M 10-Q · filed 2024-10-11 |
| 2024-05-31 | $9.38M 10-Q · filed 2024-07-11 |
| 2023-11-30 | $7.42M 10-K · filed 2025-01-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |